Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ozoralizumab (ATN-103), a humanized trivalent nanobody compound, comprises two anti-human TNFα nanobodies along with an anti-human serum albumin (HSA) nanobody, acting as an anti-TNFα humanized antibody. This compound is utilized in the research of arthritis [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Ozoralizumab (ATN-103), a humanized trivalent nanobody compound, comprises two anti-human TNFα nanobodies along with an anti-human serum albumin (HSA) nanobody, acting as an anti-TNFα humanized antibody. This compound is utilized in the research of arthritis [1]. |
Molecular Weight | N/A |
CAS No. | 1167985-17-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ozoralizumab 1167985-17-2 inhibitor inhibit